Pancreatitis

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Retrieved on: 
星期四, 四月 11, 2024
FDA, Chemoradiotherapy, Food, Pancreatic cancer, SOC, Survival, Survival rate, MD, Tumor microenvironment, Doctor of Philosophy, PDAC, CADL, Cancer, Patient, Pancreatitis, Neoplasm, Standard of care, Therapy, Injection, Lung cancer, Pharmaceutical industry

NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.

Key Points: 
  • NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
  • “We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer.”
    “Obtaining Orphan Drug Designation marks a significant milestone for Candel, as we continue to develop CAN-2409 for pancreatic cancer,” said Garrett Nichols.
  • “We are excited by this FDA designation, which further supports Candel’s efforts in the development of medicines to cure less prevalent yet challenging to treat cancers.
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Sage Veterinary Imaging Opens New Treatment Center in Spring

Retrieved on: 
星期四, 四月 11, 2024
Pain, Kidney disease, Blood, American College, ACVR, Liver disease, Pet, Skin, SVI, Glomus tumor, Heart, Echocardiography, Veterinary medicine, Brain, ACL, Stomach, Human, Limp, Pancreatitis, Radio, MRI, Biopsy, Diagnosis, Medical imaging

SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI). Working closing with local veterinarians, SVI offers the latest research-grade technology to obtain highly detailed images that enable accurate diagnosis and effective treatment plans for area pets. The new clinic is located at 8101 Cypresswood, Spring.

Key Points: 
  • SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI).
  • "Our mission is to help find answers fast using our human-quality imaging, and work with local veterinarians to deliver the treatment your pet needs."
  • Sage Veterinary Imaging is accredited by the American College of Veterinary Radiology (ACVR) as a teaching hospital, and the Spring clinic includes:
    3T magnetic resonance imaging (MRI).
  • The Spring imaging center is the third location for SVI; other imaging centers are located in Sandy, Utah, and Round Rock, Texas.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
星期四, 四月 4, 2024
Toxicity, B cell, Conditional sentence, SOC, Survival, Survival rate, Chemoradiotherapy, Patient, Neoplasm, Tumor microenvironment, Standard of care, Doctor of Philosophy, Lymphocyte, Pancreatic cancer, Therapy, Cytokine, Injection, Pancreatitis, CD8, SITC, Recurrence, Valaciclovir, FDA, Annual general meeting, CADL, Food, Pharmaceutical industry

At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Key Points: 
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.
  • Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial.
  • Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
星期一, 四月 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
星期日, 四月 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

PITTSBURGH PLASTIC SURGEON PRIORITIZES SEMAGLUTIDE PATIENT HEALTH & SAFETY THROUGH LAUNCH OF NEW PROGRAM

Retrieved on: 
星期三, 四月 3, 2024
Patient safety, Education, Patient, Weight loss, Bellissimo, GI, Skin, Pancreatitis, Nursing

PITTSBURGH, April 3, 2024 /PRNewswire/ -- Bellissimo Plastic Surgery and Medi Spa announced Tuesday the launch of its Comprehensive Semaglutide and Wellness Program .

Key Points: 
  • PITTSBURGH, April 3, 2024 /PRNewswire/ -- Bellissimo Plastic Surgery and Medi Spa announced Tuesday the launch of its Comprehensive Semaglutide and Wellness Program .
  • Bellissimo's program introduces a framework prioritizing patient health, including an initial health assessment, ongoing nutritional and medical oversight, and resources to foster long-term weight maintenance post-treatment.
  • Led by board-certified plastic surgeon Dr. Jeffrey Antimarino , Bellissimo prioritizes patient safety, education, and aesthetic results.
  • Interested individuals can schedule a consultation or call 844-496-6647 for more information on the Comprehensive Semaglutide & Wellness Program.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
星期五, 三月 8, 2024
Gastroesophageal reflux disease, Research, Heartburn, Blood, Diet, Cholesterol, Dietary supplement, Obesity, Dizziness, Pancreatitis, Vomiting, Health care, History, Thyroid cancer, Fatigue, Hypoglycemia, Acute kidney injury, Depression, Patient, Kidney disease, Abdominal distension, Burping, Cosmetics, Cardiovascular disease, Suicide, Weight, Stroke, Nausea, Diabetic retinopathy, Pancreas, Insulin, Blood pressure, Multimedia, Overweight, Diarrhea, Novo Nordisk, Vaccine, Safety, Heated tobacco product, Indigestion, Heart, Human services, Priority review, Division, Headache, Inflammation, FDA, Food, Weight loss, Thought, Heart rate, Gallstone, Risk, Animal, Allergy, Constipation, Death, Flatulence, Public

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Retrieved on: 
星期一, 二月 5, 2024
Injection, Serology, OS, Tumor microenvironment, Survival, Prostate cancer, Breast cancer, Immunotherapy, Pancreatic cancer, MD, PDAC, SITC, Enlightenment, Food and Drug Administration, Lung cancer, Society, Clinical trial, Therapy, Patient, Brain, Cancer, FDA, Biomarker, Trial of the century, Food, CADL, Fast track (FDA), CSO, Disease, Biology, Pancreatitis, Doctor of Philosophy, Valaciclovir, Conference, Pharmaceutical industry

“Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.

Key Points: 
  • “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.
  • In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer.
  • This platform is open for collaborations with external partners.”
    The Company's strategic prioritization of programs highlights Candel Therapeutics' commitment to operational excellence and efficiency.
  • This approach positions the Company for sustained success in the current dynamic market for new cancer therapeutics.

Your body already has a built-in weight loss system that works like Wegovy, Ozempic and Mounjaro – food and your gut microbiome

Retrieved on: 
星期三, 一月 17, 2024
Diabetes, Obesity, Flavonoid, Taste, Nutrient, Patient, Gastroparesis, Weight gain, Health, GIP, Depression, Addiction, Digestion, Food, Weight loss, Nausea, Sleep, Extrapyramidal system, Diet, Hormone, University, Pancreatitis, PYY, Constipation, Gastrointestinal tract, Movement, Disease, Splenic infarction, DSM-IV codes, Medicine, Carotenoid, Population, Diarrhea, Inflammation, Stroke, Stomach, Plant, Exercise, Overweight, Blood, Brain, Metabolism, Appetite, Vomiting, Cardiovascular disease, Pancreas, Polyphenol, Pharmaceutical industry

Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.

Key Points: 
  • Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.
  • They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control.
  • Here’s an inside-out perspective on the role natural gut hormones and healthy food play in metabolism and weight loss.

A broken gut

  • These include GLP-1, a natural version of Wegovy and Ozempic.
  • GLP-1 and other hormones like PYY help regulate blood sugar through the pancreas.
  • Prior to modern processed foods, metabolic regulatory pathways were under the direction of a diverse healthy gut microbiome that used these hormones to naturally regulate your metabolism and appetite.
  • Removal of these key food components and the resulting decrease in gut microbiome diversity may be an important factor contributing to the rise in obesity and diabetes.

A short track to metabolic health

  • Researchers have demonstrated their effectiveness at weight loss and blood sugar control.
  • These drugs complement other measures like gastric bypass surgery that are used in the most extreme cases of metabolic disease.
  • Medical guidelines support the use of new incretin-based medications like Wegovy, Ozempic and Mounjaro to manage the interrelated metabolic conditions of diabetes, obesity and cardiovascular disease.

A near-magic bullet – for the right folks


Despite the success and prospect of these drugs to help populations that may benefit most from them, current prescribing practices have raised some questions. Should people who are only a little overweight use these drugs? What are the risks of prescribing these drugs to children and adolescents for lifelong weight management?

  • These symptoms are related to how the drugs work to slow the gastrointestinal tract.
  • Other more severe, but rare, side effects include pancreatitis and irreversible gastroparesis, or inflammation of the pancreas and stomach paralysis.

All roads lead to lifestyle

  • Despite our greatest aspirations for quick fixes, it’s very possible that a healthy lifestyle remains the most important way to manage metabolic disease and overall health.
  • This includes regular exercise, stress management, sleep, getting outdoors and a balanced diet.


Christopher Damman is on the scientific advisory board at One BIO and Supergut.